Cointime update: China’s National Medical Products Administration has approved Eli Lilly’s Class 1 innovative drug orforglipron calcium tablets, marketed as Muyouda, for long-term weight management in adults. The drug is indicated alongside diet and exercise for adults with a baseline BMI of 30 kg/m2 or higher (obesity) or 27 kg/m2 or higher. The approval was granted to Eli Lilly Nederland B.V.
China NMPA Approves Eli Lilly’s Oral Weight-Loss Drug Orforglipron Calcium Tablets
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
13m ago
Polus Executive Warns AI Borrowing Boom Signals Weaker Credit Underwriting
1h ago
Dow Falls 1% as US Stocks Extend Losses
3h ago
Spot gold falls 2.59% to slip below $3,750/oz
5h ago
House Democrats Target Trump Inner Circle in First Oversight Requests
5h ago
US Democrats Plan Data Center Power Reform, Operators May Pay $35B More Over 10 Years
5h ago
Democrats to Probe Trump’s $100B Venezuela Oil Deal